Besponza is a combination drug used to treat relapsed or refractory CD22-positive B-cell lymphocytic leukemia. The drug consists of a humanized anti-CD22 monoclonal antibody (Inotuzumab) linked to a cytotoxic agent
Fludarabine B-cell chronic lymphocytic leukemia (CLL); Low-grade non-Hodgkin’s lymphomas Active ingredient: fludarabine sulfate 50 mg Prescription medicine.